Stocktoria
DSM-Firmenich AG DSFIR.AS
DSM-Firmenich AG (DSFIR.AS) earns a Piotroski F-score of 5/9 (mixed financial health), with an Altman Z″ in the safe zone. It pays a dividend yielding 3.49% (safety: safe). FY2025 revenue was €9.0B at a -12.0% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
Forward estimates · earnings calendar →
Consensus analyst estimates and scheduled dates — forward-looking, may change.
How it ranks in Basic Materials · percentile among 111 companies
Percentile vs other Basic Materials companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 5/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · safe zone
| Component | Value |
|---|---|
| Working capital / assets | 0.112 |
| Retained earnings / assets | 0.286 |
| EBIT / assets | 0.022 |
| Equity / liabilities | 1.67 |
About DSM-Firmenich AG
DSM-Firmenich AG provides nutrition, health, and beauty solutions in Switzerland, the Netherlands, rest of Europe, the Middle East and Africa, North America, Latin America, China, and rest of Asia. The company operates through Perfumery & Beauty; Taste, Texture & Health; and Health, Nutrition & Care segments. The Perfumery & Beauty creates scents using natural, synthetic, and biotech ingredients. The Taste, Texture & Health segment provides food and beverages solutions, including flavors, natural extracts, and sugar reduction; and food enzymes, hydrocolloids, cultures, natural colorants, nutritional ingredients, and plant-based proteins. The Health, Nutrition & Care segment provides solutions for the early life nutrition, dietary supplement, pharmaceutical, medical nutrition, biomedical materials, and nutrition improvement markets. This segment also offers vitamins, nutritional lipids, minerals, carotenoids, botanical nutraceuticals, digestive enzymes, postbiotics, probiotics and prebiotics, and active pharmaceutical ingredients; biomedical solutions; and premix, market-ready, and personalized nutrition solutions, as well as expert services in regulatory affairs and nutrition. DSM-Firmenich AG was founded in 1902 and is based in Kaiseraugst, Switzerland.
FAQ
Is DSFIR.AS financially healthy?
DSM-Firmenich AG's Piotroski F-score is 5/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the safe zone.
Does DSFIR.AS pay a dividend, and is it safe?
Yes. DSM-Firmenich AG pays a dividend yielding about 3.49% with a -66.4% payout ratio, rated “safe” for safety.
How profitable is DSFIR.AS?
In FY2025, DSM-Firmenich AG had a net margin of -12.0% and a return on equity of -5.9%.
What is the analyst price target for DSFIR.AS?
The average Wall-Street price target for DSM-Firmenich AG is €80.17, about 3.5% below the recent price, from 20 analysts (consensus: buy).
Is DSFIR.AS a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on DSM-Firmenich AG: a Piotroski F-score of 5/9, an Altman Z″ in the safe zone, a dividend yield of 3.49%. Weigh these quality and valuation signals against your own goals.
Computed from company filings · NL · as of 2025-12-31. Figures in EUR. Facts plus Stocktoria's own computed scores — not investment advice.